NTHI · Neonc Technologies Holdings, Inc.

This 8-K filing centers on material insider activity and critical financial context surrounding NeOnc’s 2025 results, elevating investor attention beyond headline losses. The $300,000 purchase by Chairman and CEO Amir Heshmatpour—disclosed explicitly as a signal of conviction in undervalued shares—coincides with two imminent clinical inflection points: the NEO100 interim data readout (~August 2026) and the NEO212 Type B FDA meeting (within 4 weeks), both of which could materially influence valuation. Crucially, the press release (Exhibit 99.1) disaggregates the $62 million GAAP net loss, revealing that $45.2 million—73%—comprised non-cash stock-based compensation ($35.6M) and one-time listing advisory fees ($9.6M). Management explicitly defines normalized cash operating expenses as $10.1 million, a non-GAAP metric intended to reflect sustainable operational cost structure. This reconciliation directly addresses investor concerns about cash runway: the $13.0 million Q1 2026 private placement strengthens liquidity, and the stated use of proceeds—repaying short-term convertible debt and settling accrued obligations—reduces near-term liabilities. CFO Keithly Garnett underscores disciplined capital allocation, framing 2025 as a year of dual advancement: clinical progress and public company transition. The emphasis on NEO100’s 24% radiographic remission rate (vs. ~8% historical salvage therapy) and NEO212’s RP2D at 610 mg with early signs of durable disease control further anchors the narrative around clinical de-risking. Collectively, the disclosure reframes financial performance, shifts focus to near-term value catalysts, and affirms management’s alignment with shareholders through direct equity investment.